Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

The development of a nanoparticle RNA vaccine is reported that preferentially targets dendritic cells after systemic administration, and is shown to provide durable interferon-α-dependent antigen-specific immunity in mouse tumour models; initial results in advanced melanoma patients indicate potential efficacy in humans. The systemic delivery of vaccine antigens into the dendritic or antigen-presenting cells of the immune system faces many...